Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 70Gastrointestinal 6Thoracic 4CNS 4Breast 4Gynecologic 3Sarcoma 2Endocrine 2Other solid neoplasm 1NET 1Head & Neck 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Triple Negative Breast Neoplasms 1Mesothelioma, Malignant 1Mesothelioma 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Advanced Malignant Solid Neoplasm 1

Interventions

pembrolizumab 10Nivolumab 5Granulocyte Colony-Stimulating Factor 4atezolizumab 3Ipilimumab 3Ifosfamide 3Etoposide 3tislelizumab 2sargramostim 2durvalumab 2Thiotepa 2Paclitaxel 2Mesna 2Melphalan 2Filgrastim 2Docetaxel 2Cyclophosphamide 2Carboplatin 2Busulfan 2tazemetostat 1spartalizumab 1regorafenib 1pegylated granulocyte colony-stimulating factor 1obinutuzumab 1niraparib 1naptumomab estafenatox 1milademetan 1etoposide phosphate 1epacadostat 1enzalutamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Renal Cell × cabozantinib × Other solid neoplasm × Clear all
NCT02071862 2022-07-20

Study of the Glutaminase Inhibitor CB-839 in Solid Tumors

Calithera Biosciences, Inc

Phase 1 Completed
210 enrolled
BreastGenitourinaryOther solid neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Mesothelioma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡